SG10201509539UA - Methods And Compositions For Inhibition Of Treg Cells - Google Patents
Methods And Compositions For Inhibition Of Treg CellsInfo
- Publication number
- SG10201509539UA SG10201509539UA SG10201509539UA SG10201509539UA SG10201509539UA SG 10201509539U A SG10201509539U A SG 10201509539UA SG 10201509539U A SG10201509539U A SG 10201509539UA SG 10201509539U A SG10201509539U A SG 10201509539UA SG 10201509539U A SG10201509539U A SG 10201509539UA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibition
- compositions
- methods
- treg cells
- treg
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000003289 regulatory T cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32355710P | 2010-04-13 | 2010-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201509539UA true SG10201509539UA (en) | 2015-12-30 |
Family
ID=44761077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012075461A SG184819A1 (en) | 2010-04-13 | 2011-04-12 | Methods and compositions for inhibition of treg cells |
| SG10201509539UA SG10201509539UA (en) | 2010-04-13 | 2011-04-12 | Methods And Compositions For Inhibition Of Treg Cells |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012075461A SG184819A1 (en) | 2010-04-13 | 2011-04-12 | Methods and compositions for inhibition of treg cells |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20110250173A1 (en) |
| EP (1) | EP2558123B1 (en) |
| JP (2) | JP6294666B2 (en) |
| KR (3) | KR20130060188A (en) |
| CN (1) | CN103002915B (en) |
| AU (3) | AU2011240752B2 (en) |
| BR (1) | BR112012026007A2 (en) |
| CA (1) | CA2796053A1 (en) |
| HK (1) | HK1184362A1 (en) |
| IL (2) | IL275017B2 (en) |
| SG (2) | SG184819A1 (en) |
| WO (1) | WO2011130249A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130249A2 (en) * | 2010-04-13 | 2011-10-20 | Immunovative Therapies, Ltd. | Methods and compositions for inhibition of treg cells |
| US10272143B2 (en) | 2014-01-08 | 2019-04-30 | Immunovative Therapies Ltd. | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
| TWI714529B (en) * | 2015-05-20 | 2021-01-01 | 以色列商梵提夫免疫療法公司 | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
| JP7033066B2 (en) * | 2016-01-07 | 2022-03-09 | ビー．ジー．ネゲブ テクノロジーズ アンド アプリケーションズ リミテッド， アット ベン‐グリオン ユニバーシティー | Compositions and Methods to Generate Immune Tolerance Responses |
| JP7002769B2 (en) * | 2016-09-16 | 2022-02-04 | ベイラー カレッジ オブ メディスン | Platform for activation and expansion of virus-specific T cells |
| CN115996737A (en) | 2020-01-10 | 2023-04-21 | 依米诺比姆有限公司 | Novel lactobacillus plantarum strain, polysaccharide derived from strain and application thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
| NZ511055A (en) * | 1998-10-05 | 2003-10-31 | Pharmexa As | Novel methods for therapeutic vaccination |
| US6797480B1 (en) | 1998-10-05 | 2004-09-28 | University Of Connecticut Health Center | Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents |
| US6875849B2 (en) | 2001-05-01 | 2005-04-05 | Arizona Board Of Regents Of Behalf Of The University Of Arizona | Methods of recovering chaperone proteins and complexes thereof |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| JPWO2003028758A1 (en) * | 2001-09-28 | 2005-01-13 | 治夫 杉山 | Method for inducing antigen-specific T cells |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| CA2598090A1 (en) * | 2005-02-17 | 2006-08-24 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Synergistic effect of tgf-beta blockade and immunogenic agents on tumors |
| US7745215B2 (en) * | 2005-12-08 | 2010-06-29 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding T regulatory cells |
| EP2003978B1 (en) * | 2006-04-13 | 2014-06-11 | Immunovative Therapies, Ltd. | Allogeneic cell therapy for treatment of opportunistic infection |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| US20080112963A1 (en) * | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| JPWO2008126940A1 (en) * | 2007-04-10 | 2010-09-24 | 国立大学法人 東京大学 | New T cells |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| US9695397B2 (en) * | 2008-10-01 | 2017-07-04 | Immunovative Therapies Ltd. | Th1 vaccination priming for active immunotherapy |
| EP2141245A1 (en) * | 2008-07-03 | 2010-01-06 | Ivana Türbachova | DNA methylation analysis of regulatory T cells through DNA-methylation analysis of the TSDR region of the gene foxP3 |
| WO2011130249A2 (en) * | 2010-04-13 | 2011-10-20 | Immunovative Therapies, Ltd. | Methods and compositions for inhibition of treg cells |
| JP6663359B2 (en) * | 2014-06-06 | 2020-03-11 | ブルーバード バイオ， インコーポレイテッド | Improved T cell composition |
-
2011
- 2011-04-12 WO PCT/US2011/032090 patent/WO2011130249A2/en active Application Filing
- 2011-04-12 KR KR1020127028850A patent/KR20130060188A/en active Application Filing
- 2011-04-12 AU AU2011240752A patent/AU2011240752B2/en active Active
- 2011-04-12 KR KR1020207014991A patent/KR20200063262A/en not_active Application Discontinuation
- 2011-04-12 CA CA2796053A patent/CA2796053A1/en active Pending
- 2011-04-12 SG SG2012075461A patent/SG184819A1/en unknown
- 2011-04-12 SG SG10201509539UA patent/SG10201509539UA/en unknown
- 2011-04-12 EP EP11769425.7A patent/EP2558123B1/en active Active
- 2011-04-12 JP JP2013505048A patent/JP6294666B2/en active Active
- 2011-04-12 US US13/084,900 patent/US20110250173A1/en not_active Abandoned
- 2011-04-12 BR BR112012026007A patent/BR112012026007A2/en not_active Application Discontinuation
- 2011-04-12 IL IL275017A patent/IL275017B2/en unknown
- 2011-04-12 KR KR1020187032175A patent/KR102117350B1/en active IP Right Grant
- 2011-04-12 CN CN201180019282.4A patent/CN103002915B/en active Active
-
2012
- 2012-10-10 IL IL222343A patent/IL222343B/en active IP Right Grant
-
2013
- 2013-09-27 HK HK13111030.4A patent/HK1184362A1/en not_active IP Right Cessation
-
2016
- 2016-04-08 JP JP2016078393A patent/JP2016155851A/en active Pending
- 2016-08-24 US US15/245,845 patent/US20160361404A1/en active Pending
- 2016-09-26 AU AU2016231642A patent/AU2016231642B2/en active Active
-
2018
- 2018-07-03 AU AU2018204834A patent/AU2018204834B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130060188A (en) | 2013-06-07 |
| AU2018204834A1 (en) | 2018-08-02 |
| IL222343A0 (en) | 2012-12-31 |
| JP2013523886A (en) | 2013-06-17 |
| IL275017B1 (en) | 2024-03-01 |
| HK1184362A1 (en) | 2014-01-24 |
| EP2558123A4 (en) | 2014-03-19 |
| KR20180123183A (en) | 2018-11-14 |
| AU2011240752B2 (en) | 2016-07-28 |
| AU2018204834B2 (en) | 2020-02-06 |
| AU2011240752A1 (en) | 2012-11-08 |
| JP6294666B2 (en) | 2018-03-14 |
| IL275017B2 (en) | 2024-07-01 |
| JP2016155851A (en) | 2016-09-01 |
| IL275017A (en) | 2020-07-30 |
| CN103002915B (en) | 2015-09-23 |
| SG184819A1 (en) | 2012-11-29 |
| KR102117350B1 (en) | 2020-06-02 |
| US20160361404A1 (en) | 2016-12-15 |
| EP2558123A2 (en) | 2013-02-20 |
| AU2016231642A1 (en) | 2016-10-27 |
| CA2796053A1 (en) | 2011-10-20 |
| WO2011130249A2 (en) | 2011-10-20 |
| KR20200063262A (en) | 2020-06-04 |
| BR112012026007A2 (en) | 2016-06-28 |
| EP2558123B1 (en) | 2023-08-09 |
| IL222343B (en) | 2020-06-30 |
| US20110250173A1 (en) | 2011-10-13 |
| CN103002915A (en) | 2013-03-27 |
| WO2011130249A3 (en) | 2012-03-08 |
| EP2558123C0 (en) | 2023-08-09 |
| AU2016231642B2 (en) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263729A (en) | Compositions and methods for the removal of biofilms | |
| EP2633046A4 (en) | Compositions and methods for inhibition of pcsk9 genes | |
| EP2603202A4 (en) | Compositions and methods for treatment of taupathy | |
| IL225672A0 (en) | Methods and compositions for inhibition of polymerase | |
| HK1220869A1 (en) | Gel-based compositions and method of making same | |
| EP2622090A4 (en) | Methods and compositions for inhibiting viral entry into cells | |
| EP2536756A4 (en) | Hsa-related compositions and methods of use | |
| EP2584897A4 (en) | Resveratrol-containing compositions and methods of use | |
| IL245535A0 (en) | Method of engrafting cells from solid tissues | |
| IL213938A0 (en) | Compositions and methods for assessing cytotoxicity of single cells | |
| EP2635254A4 (en) | Compositions and methods relating to reduced mucoadhesion | |
| HK1175947A1 (en) | Pharmaceutical compositions and methods of making same | |
| EP2593571A4 (en) | Sweetener compositions and methods of making same | |
| IL222291A0 (en) | Compositions and methods of synthesis of pyridinoylpiperidine | |
| EP2596112A4 (en) | Acetycysteine compositions and methods of use thereof | |
| EP2598150A4 (en) | Compositions for proliferation of cells and related methods | |
| ZA201300388B (en) | Compositions and methods for inhibition of the jak pathway | |
| EP2539444A4 (en) | Compositions and methods for the production of l-homoalanine | |
| HK1184362A1 (en) | Methods and compositions for inhibition of treg cells treg | |
| HK1201451A1 (en) | Compositions and methods | |
| GB201018650D0 (en) | Methods and compositions | |
| HK1254904B (en) | Compositions and methods for the alteration of xlhed phenotypes | |
| ZA201300041B (en) | Methods and compositions of beneficiation | |
| GB201001956D0 (en) | Compositions and methods for improved saccharifications of biomass | |
| AU2010900496A0 (en) | Methods and compositions for inhibiting growth of cancerous cells |